Il-11 antibodies
AssigneesSingapore Health Services Pte Ltd, National University of Singapore, Boehringer Ingelheim International GmbH
InventorsStuart Alexander Cook, Sebastian Schaefer
Life of this patent
Estimating the term…
Abstract
Provided are antigen-binding molecules capable of binding to IL-11, and methods of medical treatment and prophylaxis using the same.
Claims22
-25. (canceled)
An antigen-binding molecule which binds specifically to IL-11, wherein the antigen-binding molecule comprises:
- (i) a heavy chain variable (VH) region incorporating the following CDRs:
- HC-CDR1 having the amino acid sequence of SEQ ID NO:
- 95;
- HC-CDR2 having the amino acid sequence of SEQ ID NO:
- 96, or a variant of SEQ ID NO:
- 96 comprising one amino acid substitution;
- and
- HC-CDR3 having the amino acid sequence of SEQ ID NO:
- 97;
- and
- (ii) a light chain variable (VL) region incorporating the following CDRs:
- LC-CDR1 having the amino acid sequence of SEQ ID NO:
- 101;
- LC-CDR2 having the amino acid sequence of SEQ ID NO:
- 102, or a variant of SEQ ID NO:
- 102 comprising one amino acid substitution;
- and
- LC-CDR3 having the amino acid sequence of SEQ ID NO:
- 103.
A nucleic acid, or a plurality of nucleic acids, encoding an antigen-binding molecule which binds specifically to IL-11, wherein the antigen-binding molecule comprises:
- (i) a heavy chain variable (VH) region incorporating the following CDRs:
- HC-CDR1 having the amino acid sequence of SEQ ID NO:
- 95;
- HC-CDR2 having the amino acid sequence of SEQ ID NO:
- 96, or a variant of SEQ ID NO:
- 96 comprising one amino acid substitution;
- and
- HC-CDR3 having the amino acid sequence of SEQ ID NO:
- 97;
- and
- (ii) a light chain variable (VL) region incorporating the following CDRs:
- LC-CDR1 having the amino acid sequence of SEQ ID NO:
- 101;
- LC-CDR2 having the amino acid sequence of SEQ ID NO:
- 102, or a variant of SEQ ID NO:
- 102 comprising one amino acid substitution;
- and
- LC-CDR3 having the amino acid sequence of SEQ ID NO:
- 103.
A method of treating or preventing a disease or condition in a subject, the method comprising administering to a subject in need thereof a therapeutically or prophylactically effective amount of an antigen-binding molecule that specifically binds to IL-11, wherein the antigen-binding molecule comprises:
- (i) a heavy chain variable (VH) region incorporating the following CDRs:
- HC-CDR1 having the amino acid sequence of SEQ ID NO:
- 95;
- HC-CDR2 having the amino acid sequence of SEQ ID NO:
- 96, or a variant of SEQ ID NO:
- 96 comprising one amino acid substitution;
- and
- HC-CDR3 having the amino acid sequence of SEQ ID NO:
- 97;
- and
- (ii) a light chain variable (VL) region incorporating the following CDRs:
- LC-CDR1 having the amino acid sequence of SEQ ID NO:
- 101;
- LC-CDR2 having the amino acid sequence of SEQ ID NO:
- 102, or a variant of SEQ ID NO:
- 102 comprising one amino acid substitution;
- and
- LC-CDR3 having the amino acid sequence of SEQ ID NO:
- 103;
- wherein the disease or condition is selected from the group consisting of:
- fibrosis, a disease characterised by fibrosis, a cancer, inflammation, a disease characterised by inflammation, hepatotoxicity, a disease characterised by hepatotoxicity, a metabolic disease, a wasting disorder, kidney injury, nephrotoxicity, and a disease characterised by hepatotoxicity.
An antigen-binding molecule which binds specifically to IL-11, wherein the antigen-binding molecule comprises:
- (i) a heavy chain variable (VH) region incorporating the following CDRs:
- HC-CDR1 having the amino acid sequence of SEQ ID NO:
- 95;
- HC-CDR2 having the amino acid sequence of SEQ ID NO:
- 96;
- and
- HC-CDR3 having the amino acid sequence of SEQ ID NO:
- 97;
- and
- (ii) a light chain variable (VL) region incorporating the following CDRs:
- LC-CDR1 having the amino acid sequence of SEQ ID NO:
- 101;
- LC-CDR2 having the amino acid sequence of SEQ ID NO:
- 102;
- and
- LC-CDR3 having the amino acid sequence of SEQ ID NO:
- 103.
Dependencies are inferred from the claim text.